Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marisa Iborra

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 14, 2024
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort studyPatricia Sanz Segura, Fernando Gomollón, Diego Casas, et al.
Alimentary Pharmacology & Therapeutics|October 4, 2018
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryMaría Chaparro, Ana Garre, Elena Ricart, et al.
Pharmaceutics|May 25, 2024
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDACelia Gómez-Labrador, Elena Ricart, Marisa Iborra, et al.
Therapeutic Advances in Gastroenterology|January 8, 2024
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registryMargalida Calafat, Paola Torres, Joan Tosca-Cuquerella, et al.
The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Gut|January 11, 2025
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCUJavier P Gisbert, María G Donday, Sabino Riestra, et al.
Journal of Crohn'S & Colitis|August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA RegistryDiego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
Journal of Crohn'S & Colitis|April 16, 2021
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA RegistryMaría Chaparro, Ana Garre, Marisa Iborra, et al.
Journal of Crohn'S & Colitis|May 8, 2019
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort StudyIvan Guerra, Luis Bujanda, Jesús Castro, et al.
Alimentary Pharmacology & Therapeutics|June 29, 2024
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registryRocío Ferreiro-Iglesias, Sol Porto Silva, Sandra Marín, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 14, 2024
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort studyPatricia Sanz Segura, Fernando Gomollón, Diego Casas, et al.
Alimentary Pharmacology & Therapeutics|October 4, 2018
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryMaría Chaparro, Ana Garre, Elena Ricart, et al.
Pharmaceutics|May 25, 2024
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDACelia Gómez-Labrador, Elena Ricart, Marisa Iborra, et al.
Therapeutic Advances in Gastroenterology|January 8, 2024
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registryMargalida Calafat, Paola Torres, Joan Tosca-Cuquerella, et al.
The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Gut|January 11, 2025
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCUJavier P Gisbert, María G Donday, Sabino Riestra, et al.
Journal of Crohn'S & Colitis|August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA RegistryDiego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
Journal of Crohn'S & Colitis|April 16, 2021
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA RegistryMaría Chaparro, Ana Garre, Marisa Iborra, et al.
Journal of Crohn'S & Colitis|May 8, 2019
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort StudyIvan Guerra, Luis Bujanda, Jesús Castro, et al.
Alimentary Pharmacology & Therapeutics|June 29, 2024
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registryRocío Ferreiro-Iglesias, Sol Porto Silva, Sandra Marín, et al.
Pageof 10